Stockscreener 앱 받기
1.71
4.47%
-0.08
시간 외 거래:
1.66
-0.05
-2.92%
전일 마감가:
$1.79
열려 있는:
$1.79
하루 거래량:
56,438
Relative Volume:
1.48
시가총액:
$72.45M
수익:
$7.78M
순이익/손실:
$-46.20M
주가수익비율:
-2.0314
EPS:
-0.8418
순현금흐름:
$-34.08M
1주 성능:
+3.64%
1개월 성능:
-1.72%
6개월 성능:
-30.20%
1년 성능:
-38.93%
1일 변동 폭
$1.67
$1.83
1주일 범위
$1.62
$1.98
52주 변동 폭
$1.51
$2.94
InspireMD Inc. Stock (NSPR) Company Profile
명칭
InspireMD Inc.
전화
972 3 6917691
주소
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.71 | 75.84M | 7.78M | -46.20M | -34.08M | -0.8418 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Maxim Group | Buy |
| 2016-01-07 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 개시 | Oppenheimer | Outperform |
InspireMD Inc. 주식(NSPR)의 최신 뉴스
InspireMD revenue up 62% to USD 3.1M in Q4 2025 - Medical Buyer
Returns Recap: Can InspireMD Inc outperform in the next rallyDay Trade & Safe Entry Trade Reports - baoquankhu1.vn
InspireMD’s Growth Hinges on Real CAS Market Size and Physician Adoption - TipRanks
InspireMD Reports 62% Q4 Revenue Growth and Sets 2026 Outlook for CGuard Prime Carotid Stent System - Minichart
InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading - MSN
InspireMD earnings beat by $0.05, revenue topped estimates - Investing.com Canada
InspireMD, Inc. (NSPR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
InspireMD Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats - Investing.com
InspireMD, Inc. Overview: CGuard Carotid Stent Technology, Business Strategy, and Market Leadership in Stroke Prevention 72 - Minichart
InspireMD Reports Strong Q4 2025 Growth and Expansion - TipRanks
FDA PMA and global expansion reshape InspireMD (NSPR) carotid focus - Stock Titan
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
InspireMD Q4 net income USD -11.761 million - marketscreener.com
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
INSPIREMD ($NSPR) Releases Q4 2025 Earnings - Quiver Quantitative
[8-K] InspireMD, Inc. Reports Material Event | NSPR SEC FilingForm 8-K - Stock Titan
InspireMD Q4 revenue rises 62%, beats estimates - TradingView
Stroke stent maker InspireMD lifts sales 62% and targets up to $15M in 2026 - Stock Titan
921,587 Shares in InspireMD, Inc. $NSPR Purchased by Ghisallo Capital Management LLC - MarketBeat
Stock Recap: Is InspireMD Inc a momentum stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Rosalind Advisors Inc. Purchases 1,616,644 Shares of InspireMD, Inc. $NSPR - MarketBeat
InspireMD (NSPR) price target increased by 25.00% to 5.10 - MSN
Aug Opening: Can InspireMD Inc outperform in the next rally2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
Aug PreEarnings: Is InspireMD Inc stock risky to hold now2026 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
InspireMD, Inc. Scheduled to Release Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Carotid stent developer InspireMD sets March 18 results call - Stock Titan
InspireMD (NSPR) price target decreased by 11.11% to 4.08 - MSN
Is InspireMD Inc. stock dividend yield sustainableWeekly Risk Report & Verified Momentum Watchlists - Naître et grandir
InspireMD Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
InspireMD Announces Planned Departure of Chief Operating Officer - TipRanks
InspireMD announces dismissal of chief operating officer Andrea Tommasoli By Investing.com - Investing.com South Africa
InspireMD announces dismissal of chief operating officer Andrea Tommasoli - Investing.com
Embolic Protection Devices Market to Reach USD 1,161.31 Million by 2032, Growing at a CAGR of 7.58% | DelveInsight - Barchart.com
InspireMD dismisses COO Andrea Tommasoli; last day expected Sept 1, 2026 - TradingView
InspireMD (NSPR) outlines COO dismissal, French-law notice and €61k severance - Stock Titan
InspireMD, Inc. Announces Dismissal of Chief Operating Officer Andrea Tommasoli, Effective April 1, 2026 - marketscreener.com
Tangible book value per share of InspireMD Inc. – LSX:A3CMP3 - TradingView
NSPR Technical Analysis & ETF Price Forecast - Intellectia AI
Can InspireMD Inc. outperform in the next rallyJuly 2025 Market Mood & AI Powered Buy and Sell Recommendations - mfd.ru
NSPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stock Report: Why is InspireMD Inc stock going upEarnings Growth Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
InspireMD (NSPR) Price Target Increased by 25.00% to 5.10 - Nasdaq
Lake Street reiterates InspireMD stock rating citing market growth By Investing.com - Investing.com Canada
Director adds 2,710 InspireMD (NSPR) shares in amended Form 4 - Stock Titan
What hedge fund activity signals for InspireMD Inc. stock2025 Growth vs Value & Detailed Earnings Play Strategies - mfd.ru
Aberdeen Group plc Makes New Investment in InspireMD, Inc. $NSPR - Defense World
Can InspireMD Inc. ride the EV wavePortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - mfd.ru
Is InspireMD Inc. stock a top momentum playJuly 2025 Highlights & Weekly Breakout Stock Alerts - mfd.ru
InspireMD Inc. (NSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):